Active Not RecruitingNot applicableNCT05306288

CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

CASCADE-LUNG is a multisite, prospective, observational, blood specimen collection study in the elevated-risk lung cancer screening population. The primary objective is to demonstrate the performance characteristics, including sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the DELFI Lung Cancer Screening Test (DLCST) for the detection of pathologically-confirmed lung cancer in a screening population using LDCT, pathology, and follow-up as the reference method.

Checked against the public recordLast updated Mar 19, 2026 · Source: ClinicalTrials.gov

StatusActive Not Recruiting
PhaseNot applicable
U.S. locations67
SponsorDelfi Diagnostics Inc.
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Delfi Diagnostics Inc.
Interventions being studied
Other: Blood Sample Collection
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * All subjects 1. Ability to understand and provide written informed consent 2. Age ≥ 50 years 3. Current or former smoker 4. ≥ 20 pack-years (pack years = number of packs per day × number of years smoked) 5. An initial or annual follow-up lung cancer screening chest CT planned/scheduled within 30 days after enrollment (i.e., enrollment chest CT scan) Exclusion Criteria: * All subjects 1. Evidence of any diagnosed cancer (including prior lung cancer) other than non-melanoma skin cancer or carcinoma in situ within 2 years prior to enrollment 2. Prior systemic therapy, definitive therapy, radiation, or surgical resection for any cancer diagnosis within 2 years prior to enrollment (with the exception of surgery for nonmelanoma skin cancer and biopsies) 3. Any history of hematologic malignancy or myelodysplasia within 2 years prior to enrollment 4. Any history of organ tissue transplantation 5. Any history of blood product transfusion within 120 days prior to enrollment 6. Current pregnancy 7. Any condition that in the opinion of the Investigator should preclude the participant's participation in the study 8. Past or current participation in any clinical study sponsored by DELFI Diagnostics or any history of a LDT (Laboratory Developed Test) for early detection of lung cancer by DELFI Diagnostics

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Cullman Clinical TrialsCullman, Alabama
  • Science 37 (nationwide digital enrollment)Culver City, California
  • Providence Facey Medical FoundationMission Hills, California
  • Hoag HospitalNewport Beach, California
  • Paradigm Clinical Research Center, Inc.Redding, California
  • San Francisco VASan Francisco, California
  • Clinical Research of California LLCWalnut Creek, California
  • SCL Health Research Institute, St. Mary'sGrand Junction, Colorado
  • Paradigm Clinical Research CenterWheat Ridge, Colorado
  • Stamford HealthStamford, Connecticut
  • Advanced ResearchBoynton Beach, Florida
  • Morton Plant HospitalClearwater, Florida

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 19, 2026. Always confirm current availability with the study team.

View original record ↗